What it is (one line): the claim that medicine will one day add more than a year of remaining life for every year that passes — and, on Moonshots with Peter Diamandis, a date: cited in 25 of 89 indexed episodes, 81 mentions, almost always attached to a year.
Updated 2026-11-16. Refreshed weekly (see How this page stays current at the bottom). The 2026-10-05 edition added four things: who the players are, David Sinclair's six appearances on the show, the papers behind the reprogramming claims, checked at the source, and a model of what LEV is made of, so each week's news can be placed against a component instead of a date.
Why it is in this archive
Gate: cited in 25 episodes with no page (the research archive, promotion candidates). Promoted on 2026-09-24 off the Moonshots #290 decomposition — the episode where the show's own guest, who manufactures the organs, refused to name the year, and where the host revised his own public forecast on tape.
It is also the load-bearing concept under the whole health lane: the Fountain Life reads, the "live long enough to get to the bridge" frame, and every longevity story is landed on it.
The definition, as the show uses it
Peter states it plainly while correcting the guest mid-answer:
"he would define it as for every year that transpires gain more than a year of life" — Peter Diamandis, Moonshots #290
0:13:19
And, as the operator instruction it becomes: "Your goal is to live long enough to get a breakthrough to the other side." The concept originates with Aubrey de Grey; on this show it is attributed almost exclusively to Ray Kurzweil.
The date, across the corpus — and it moves
This is the point of the page. The number is not stable, and it has never been presented as unstable.
| episode | on tape | verbatim |
|---|---|---|
Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:13:31 |
end of 2030 | "his prediction is that we'll reach longevity escape velocity by the end of the year 2030" — Peter, on Kurzweil |
moonshots 217 0:59:18 |
early 2030s | "He predicted that in the early 2030s" — Peter, on Kurzweil |
moonshots 201 1:41:32 |
2032 | "Ray Kerszswwell reinforces his optimism on longevity escape velocity lev by 2032" |
moonshots 217 1:01:20 |
2030–2032 | "the AIS that I chat with think we hit longevity escape velocity sometime between 2030 and 2032" — Peter |
moonshots 235 1:46:37 |
2033, adopted as his own | "Ray … has famously said, 'LEV by 2033.' That's my war cry, 'LEV by 2033.'" — Peter |
moonshots 253 1:17:41 |
early 2030s | "perhaps sometime by the early 2030s, if not earlier" — Alexander Wissner-Gross |
moonshots 262 1:36:21 |
2033 | "what Ray Kurszwell calls longevity escape velocity by 2033" |
Moonshots #290 0:12:01 |
2033 (opening position) | "he sort of predicts LEV by the early 2030s. My my mantra is LEV by 2033." — Peter |
Moonshots #290 0:22:33 |
→ 2034–2035 | "So, let's give ourselves one or two more years than 2033." — Rothblatt. Peter: "All right. All right. I will." |
The Moonshots #290 exchange is the only revision of that number in the corpus, and it is
delivered as a joke about a t-shirt, not as news. Note what Peter accepts it on: a space timeline
miss — "I remember in the in the 80s, you know, mass drivers and mining the moon and solar power
satellites were just on the next horizon. It's taken 40 years" 0:22:12.
Two more things the table shows, added 2026-09-29.
The date attributed to Kurzweil drifts on the show: end of 2030 → early 2030s → 2032 → 2033. It is quoted as one fixed prediction each time.
The condition falls off. Kurzweil's own versions carry a qualifier. His 2024 book, as quoted in excerpts: "By around 2030, the most diligent and informed people will reach longevity escape velocity." At the 2024 Abundance Summit: "For those in reasonably good shape and with reasonable means, I believe they will have access to longevity escape velocity by the end of 2030" (diamandis.com). ⚠️ The book wording is taken from quoted excerpts and has not been checked against the book itself.
Kurzweil's own date moves too (added 2026-10-29). At MIT on 8 Oct 2025 (Robert A. Muh Alumni Award lecture, Reinventing Intelligence), as reported by MIT News on 10 Oct 2025: "By roughly 2032 when you live through a year, you'll get back an entire year from scientific progress", with the advances said to "start" with the people most diligent about their health (MIT News; text read via a search extract, page not opened directly ⚠️). So his stated year went from end of 2030 (2024) to roughly 2032 (2025), and the condition stayed. The show's 2032 (moonshots 201) matches this later version (its wording, "reinforces his optimism", echoes the MIT News headline); "LEV by 2033" still matches neither.
The claim on stage is about a subset of people, and the version on the show is about everyone. This is the same one-hedge-per-hop compression documented for the Moonshots #293 exhibits below. When Kurzweil was the guest on moonshots 261 (2026-06-03), he did not give a LEV year in the parts of the transcript that were searched (SWEPT, not read end to end). The line "we're about to achieve longevity escape velocity here" at
1:10:30is a joke about three generations on one stage, answered with "That's true." The speakers are inferred from the hand-offs, because auto-captions carry no speaker labels.
The dissent, on their own tape
The show treats LEV as settled. Two of the most credible voices on the tape do not.
Martine Rothblatt — the guest who actually manufactures transplantable organs:
"it is the most extraordinary of extraordinary claims. And I believe in this adage that extraordinary claims require extraordinary evidence." (Moonshots #290
0:12:26) "to pin it to a specific year is … beyond my risk profile." (0:13:49)She substitutes a mechanism for a date — "restore, replace, renew" (
0:13:59) — and a narrower claim: "can we add 30 extra healthy years on your life" (0:13:09).A guest on moonshots 253
0:43:31: "while longevity escape velocity to me seems absurd, are we going to live a lot longer? Hell, yes."
The practitioner's confidence is lower than the forecasters'. That is the finding, and it is the inverse of how the concept is presented in the other 24 episodes.
The players
These are the people and organisations the LEV claim rests on. Each row gives the role they play, their own claim or timeline (dated, in their words where possible), their position and disclosed ties, and whether they have appeared on Moonshots with Peter Diamandis. The appearance search covered all ~900 uploads on the channel's video tab plus its shorts, stream and title list, on 2026-09-29. "Named" means they are mentioned without being a guest.
| who | role in LEV | claim / timeline | position and disclosed ties | on Moonshots |
|---|---|---|---|---|
| Aubrey de Grey | Originated the concept. Frames ageing as repairable damage (SENS). | "I now think there is a 50% chance that we will reach longevity escape velocity by 2036" (X, 2021-03-14, primary). The "12–15 years" figure is now in his own words (added 2026-11-10): "I currently think that we've got a fifty-fifty chance of getting there within the next twelve to fifteen years", where "there" is "bring human aging under comprehensive medical control" (Honest Money LIVE EP 006, 4 Nov 2026, transcript read on the episode page). On a 7 Nov podcast (Futureproof Report) he attaches the same 50/50 and 12–15 years to LEV itself, adding "at least a 5% chance that we won't get there for 100 years". On another 7 Nov podcast (Kianistan EP 178) he puts it at "the late 2030s, maybe 2037 to 2040", says he said "the region of 2030" in 2004–05, and that the slip all happened by 2015. (The two 7 Nov quotes come from transcript excerpts found by search; the videos were not watched ⚠️.) Counted from 2026, 12–15 years is 2038–2041, so the three line up roughly. The New York Times (2026-10-14, "Will Anyone Actually Ever Live to 200?") attributes to him "a greater than 50 percent chance that a 40-year-old living today will never die of old age" (secondary, seen in a search excerpt, article not opened). A new podcast interview with him was posted 2026-10-16 (Jon Hernandez, YouTube 77wO0SM8QMI); not read, so no year has been taken from it. |
President and CSO, LEV Foundation (self-reported, LEVF Dec 2025). Co-founded SENS Research Foundation; its board separated from him in Aug 2021 (STAT). | Never a guest in the titles searched. Named: moonshots 279 0:07:58 (Peter: "who coined the term longevity escape velocity, and then… Ray popularized it") · moonshots 273 1:44:26, 1:51:04 · Moonshots #288 2:14:44 · Moonshots #294 0:48:58 |
| Ray Kurzweil | Supplies the date the show uses. | "By around 2030, the most diligent and informed people…" (2024 book, quoted excerpt ⚠️). "End of 2030" for "those in reasonably good shape and with reasonable means" (Abundance Summit 2024). "By roughly 2032", starting with the most diligent (MIT lecture, 8 Oct 2025, per MIT News ⚠️ search extract). On his own guest episode he restates it as AGI 2029 / singularity 2045 (moonshots 261 0:12:09) — not an LEV date itself, but the compute curve the show's LEV claims lean on. |
Director of United Therapeutics since 2002 (UTHR 2026 proxy, primary). That makes him a board member of Martine Rothblatt's company. | Guest: moonshots 261 (2026-06-03, read end to end 2026-10-01), and earlier (EP #125, #95, #83, not ingested). The date is quoted by Peter throughout. → now has his own page, Ray Kurzweil. |
| David A. Sinclair | Epigenetic reprogramming (OSK): the "reset" component. Also the "information theory of ageing." | "I don't have a number" on LEV (Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:14:40). "the first person to live to 150 has already been born" (0:15:42). "It may be 2026 is the year we learn that age reversal is possible in humans" (moonshots 249 0:12:59). |
Co-founder, Life Biosciences (ER-100). His conflict-of-interest statement in the 2023 papers lists Life Bio, Tally Health, Animal Biosciences, InsideTracker, Zymo, MetroBiotech and others (PubMed 36638792). Lab partly funded by the Friends of Sinclair Lab set up on this show. | Guest six times (see the next section). Return announced on Moonshots #288 2:19:11. |
| Shinya Yamanaka | Discovered the factors (OSKM, 2006) that every reprogramming programme descends from. | Makes no LEV claim of his own that was found. | 2012 Nobel (shared with John Gurdon). Senior Investigator at Gladstone and professor at CiRA, Kyoto. Senior scientific adviser to Altos Labs "without remuneration" (Altos launch, 2022-01-19, primary). | Never a guest. Named: moonshots 217 0:56:54 · moonshots 190 1:33:54 · moonshots 273 1:41:14 |
| Martine Rothblatt | Replacement: manufactured organs and the thymus. | "to pin it to a specific year is … beyond my risk profile" (Moonshots #290 0:13:49). |
Founder, Chair and CEO of United Therapeutics. UKidney EXPAND trial: IND cleared 2025-02-03, first transplant announced 2025-11-03 (UTHR). Kurzweil sits on her board. | Guest: Moonshots #290 |
| Peter Diamandis | Host and chief evangelist. | "LEV by 2033", his "war cry" (moonshots 235 1:46:37); he accepted "one or two more years" on Moonshots #290 0:22:33. |
Co-founder of Fountain Life. Founder and executive chairman of XPRIZE, which runs XPRIZE Healthspan, and "a multi-million dollar donor" to it (Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:31:02). Life Biosciences investor, self-disclosed on tape ("full disclosure life bioscience is one of my portfolio companies", moonshots 273 1:41:03; "investors along with me in Life Biosciences", moonshots 249 0:03:43); no filing found. Put up the first $50K for Friends of Sinclair Lab (moonshots 249 0:18:42). |
Host |
| Altos Labs | The best-funded reprogramming effort. | No public LEV date. No human trial announced as of 2026-09-29. | Launched 2022-01-19 with "$3 billion fully committed" (primary). The release names no backers; Bezos and Milner come from press reports (secondary). CEO Hal Barron; institute directors include Juan Carlos Izpisua Belmonte, author of the 2016 partial-reprogramming paper below. | Named: moonshots 273 1:41:26 · moonshots 262 1:40:02 |
| Retro Biosciences | Autophagy, plasma and reprogramming programmes. | Mission: "add ten years to healthy human lifespan" (retro.bio, 2026-05-22, primary). That is a healthspan target, not LEV. | Seeded with $180M from Sam Altman (MIT Tech Review, 2023, secondary). Round of 2026-05-22 at a $1.8B pre-money valuation; amount not disclosed. RTR242 (autophagy, oral) is in Phase 1 in healthy volunteers in Adelaide; no results published as of 2026-09-29. | Named: moonshots 273 1:41:14 · moonshots 262 |
| NewLimit | Epigenetic reprogramming, liver first. | First human trial planned for 2027 (the company earlier said it might be as late as 2030). | Brian Armstrong, Blake Byers and Jacob Kimmel. $435M Series C, 2026-06-02, led by Founders Fund (NewLimit, primary). The $3.1B valuation said on moonshots 262 1:39:18 matches press reports (secondary); the company did not state it. |
Named: moonshots 262 · moonshots 170 0:46:59 |
| XPRIZE Healthspan + Hevolution | Turns "reverse ageing" into a measurable target. | $101M over 7 years to restore muscle, cognitive and immune function by at least 10 years (20-year target) with a treatment of 1 year or less. 10 finalists got $1M each on 2026-08-11; grand prize of up to $81M in 2030 (XPRIZE, primary). ⚠️ The target age band differs between releases: 65–80 at launch, 50–90 in 2026. | Co-title sponsors: Hevolution Foundation (Riyadh; "annual budget of up to $1 billion", its own description) and Chip Wilson / SOLVE FSHD. Peter is XPRIZE's founder and a donor. Sinclair's lab has entered a chemical cocktail (moonshots 249 0:09:28). |
Recurring. The origin story is on Moonshots #294 0:48:58: Thiel and de Grey proposed a longevity prize, and George Church suggested measuring age reversal instead. |
| Bryan Johnson | Tests the bridge on himself, in public (Blueprint, "Don't Die"). | "I have the world's slowest speed of aging: 0.48" (DunedinPACE, his blog, 2025-05-20). Self-reported, n=1, no peer-reviewed paper found. | Founder of Blueprint, which sells the products of the protocol. | Never a guest. Named once: moonshots 248 2:03:02 |
| Alexander Wissner-Gross | Panel forecaster. | "perhaps sometime by the early 2030s, if not earlier" (moonshots 253 1:17:41). On Moonshots #unnumbered 1:19:48, no year: nanotech, LEV and superintelligence arrive "at approximately the same time", as "one big hairball". On X, 2026-10-13, he named "Spiky LEV": "the hypothesis that longevity escape velocity is already emerging in narrow subpopulations, under specific interventions, over limited time windows, long before it appears in population-wide averages" (post 2109986478348501474, text from a search excerpt, not opened directly ⚠️). That is the subset claim (Kurzweil's "most diligent and informed") turned into a definition, and it makes LEV unfalsifiable at population scale, which is the scale the gauge below measures. His page bars it as a claim; it is captured here as a framing. It reached the tape on Moonshots #304 (2026-10-21) 1:12:35, in passing and with no year: "I'm the one banging banging the drum that we may already be in spiky LEV", in reply to Peter's "the GLP-1 drugs are slowing aging by 9%" (see What fails verify-first). |
See his page. | Panelist |
Reading the table. The people closest to the bench give the least confident dates:
- Sinclair: "I don't have a number."
- Rothblatt: "beyond my risk profile."
- Retro's stated goal is ten healthy years, not escape.
The firm dates come from the forecasters (Kurzweil, de Grey) and from the host. That repeats, across the whole field, the pattern Moonshots #290 showed inside one episode.
David Sinclair on Moonshots
→ He now has his own page: David A. Sinclair (created 2026-09-30). The model, the falsification answer, his ties and the full claim table live there. What stays here is only what bears on LEV.
Search run 2026-09-29. The full channel video list (~904 uploads), the shorts tab and the streams
tab were pulled with yt-dlp, and the titles were grepped for Sinclair, de Grey, Aubrey, Kurzweil,
Yamanaka and longevity terms. The local corpus was grepped as well (86 transcripts on disk before
this pass).
He has been a guest six times. The three most recent appearances were ingested for this page, into
the research archive, ep251-sinclair-glp1-blindness/
and ep2025-06-25-sinclair-age-reversing/.
| date | episode | read |
|---|---|---|
| 2022-12-29 | Why Aging is a Disease — EP #18 · and David Sinclair's AMA | not ingested |
| 2023-08-24 | Aging is Now Optional — EP #60 | not ingested |
| 2025-06-25 | Harvard Prof Reveals Age-Reversing Science… (2h23, unnumbered) → Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair | ★ READ END TO END 2026-09-30 (was swept). All six swept claims confirmed; eleven added. the research archive |
| 2026-04-27 | David Sinclair on the Longevity Pill, Age Reversal Timelines… — moonshots 249 (on stage, Abundance event) | READ END TO END |
| 2026-04-28 | David Sinclair: GLP-1 Side Effect…, AI in His Lab & Reversing Blindness — moonshots 251 (audience Q&A) | READ END TO END |
| announced | "We're going to have David Sinclair back on this pod uh with all of us" — Peter, Moonshots #288 2:19:11 |
not yet aired |
His claims on tape, and where each one stands:
| claim | where | status |
|---|---|---|
| On LEV: "I don't have a number", then "I do believe that we could double the human lifespan now" | Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:14:40, 0:15:32 |
His own position is no date. Doubling is stated as a belief. |
| "the first person to live to 150 has already been born" | 0:15:42 |
Forecast. Aspiration: investigate |
| ER-100 going "into humans next year in January hopefully" | 0:06:05 |
Close: IND cleared 2026-01-28, study start 2026-03-02, first patient dosed per a Life Bio release of 2026-06-09. It slipped by months, not years. |
| In green monkeys "it's looking like 95% of the age goes backwards" in the optic nerve | 0:09:47 |
Self-reported and unpublished. The primate data exists only as conference presentations (ARVO 2023, AAO 2024, Life Bio). No peer-reviewed paper was found. Do not repeat the 95%. |
| "It may be 2026 is the year we learn that age reversal is possible in humans" | moonshots 249 0:12:59 |
The Phase 1 is a safety study of up to 18 eyes; primary completion is May 2027. Aspiration: investigate. Re-check in 2027. |
| A chemical cocktail into a human trial "within the next couple of months as part of our Xprize" | moonshots 249 0:09:28 |
No registry entry found this pass. Aspiration: investigate |
| Wet and dry macular degeneration "reversible to some extent in gold standard animal models", "on the radar" for ER-100 "pending results in glaucoma" | moonshots 251 0:21:20 |
Animal data, partly unpublished. This is where Peter's "macular degeneration" on Moonshots #293 came from, and it is still not a trial indication. |
| GLP-1 drugs: "about 20 to 30,000 people in the US a year" waking up blind (NAION) | moonshots 251 0:04:28 |
🔴 Off. Estimated US NAION incidence from all causes is about 6,000 a year (secondary; population-study base rate 2.3–10.2 per 100,000 over age 50). The EMA's safety committee (6 Jun 2025) calls NAION a "very rare" semaglutide side effect, about 1 extra case per 10,000 patient-years (EMA). He named NAION as an ER-100 target in the same answer and made no disclosure on air. |
| Friends of Sinclair Lab: ~70 members, "on the order of six million dollars of private annual support" | moonshots 249 0:19:36, 0:23:19 |
Self-reported (the figure is Peter's; Sinclair gives the member count). |
What the show did for him, disclosed on its own tape. On the 2025 episode his federal grants had been
terminated ("100% of those grants were terminated", 0:57:55). Peter set up Friends of Sinclair
Lab on air, put in the first $50K, and asked the audience to join (moonshots 249 0:18:42,
Moonshots #288 2:19:21). Peter is also a Life Bio investor (self-disclosed, above). The relationship
is out in the open, which is to the show's credit. It still means the guest describing ER-100 and the
host promoting it both have money in it. See Moonshots: the disclosures ledger.
Not for this page. On moonshots 249 (0:24:12–0:29:04) Sinclair describes his personal
supplement and drug routine. It is not reproduced here, because this page does not give medical advice.
The three mentions on recent episodes, with speakers
| episode | time | speaker | what is said |
|---|---|---|---|
| Moonshots #288 | 2:19:11–2:20:08 |
Peter | "We're going to have David Sinclair back on this pod… I organized on this podcast something called friends of Sinclair Lab… people like myself contributing 50k… he's using AI uh to discover molecules uh that are able to do epigenetic age reversal." |
| Moonshots #290 | 0:25:44–0:25:54 |
Peter, then Rothblatt | Peter: "the work that David Sinclair is doing with life biosciences and… partial epigenetic reprogramming. Are you tracking…?" Rothblatt: "we're not tracking uh David's work in particular, but I'm a huge fan of Dr. Sinclair." |
| Moonshots #293 | 0:27:40, 0:56:50, 0:57:30 |
Peter; a caller | The ER-100 exhibit, a caller naming Sinclair, and Peter's ER-100 answer on choroideremia. All three are checked in the ★★ table below. |
Speakers are inferred from hand-offs; Moonshots #293 is a whisper transcript.
The papers: Sinclair, Yamanaka, and what was actually shown
No paper co-authored by Sinclair and Yamanaka was found (PubMed: Sinclair DA[au] AND Yamanaka S[au] returned 0 results, 2026-09-29). The link between them is the factors. Sinclair's lab uses
three of the four Yamanaka factors. ⚠️ There is a second candidate for "the Japanese researcher": the
2023 Cell paper's second author, Motoshi Hayano (Keio University), and its co-author Kazuo
Tsubota (Keio). Which one was on stage with Sinclair is still open.
| paper | organism | what it showed | what it did not show |
|---|---|---|---|
| Takahashi & Yamanaka, Cell 2006, 10.1016/j.cell.2006.07.024 | mouse cells, in vitro | Four factors (Oct3/4, Sox2, c-Myc, Klf4: OSKM) turn adult fibroblasts into pluripotent stem cells (iPS). Basis of the 2012 Nobel. | Anything about ageing. And iPS cells formed tumours (teratomas) when transplanted, which is why the later work drops or limits the factors. |
| Ocampo … Izpisua Belmonte, Cell 2016, 10.1016/j.cell.2016.11.052 | mouse | Short, cyclic OSKM expression eased ageing hallmarks and extended lifespan in a progeria (premature-ageing) mouse, and improved recovery from injury in old normal mice. | Lifespan extension in normally ageing animals. |
| Lu … Sinclair, Nature 2020, 10.1038/s41586-020-2975-4 | mouse | Three factors (OSK, no c-Myc) delivered to retinal ganglion cells restored youthful DNA-methylation patterns, regenerated axons after optic-nerve injury, and reversed vision loss in a mouse glaucoma model and in aged mice. It required the TET1/TET2 demethylases. This is the science behind ER-100. | Humans. Also, visual acuity was "not seen" to recover in 18-month-old mice (corneal opacity, per the paper). |
| Yang, Hayano … Sinclair, Cell 2023, 10.1016/j.cell.2022.12.027 (erratum 2024) | yeast → engineered mice ("ICE") | Inducing DNA breaks at about 20 sites (repaired faithfully) accelerated ageing signs in mice: epigenetic erosion, loss of cell identity, and a faster methylation clock. OSK reversed some of this. Offered as support for the "information theory of ageing." | That this is how natural ageing happens. The model induces the damage. The abstract's own claim is that the data are "consistent with" the theory. |
| Yang … Sinclair, Aging 2023, 10.18632/aging.204896 | human and mouse cells, in vitro | Six chemical cocktails restored a youthful transcript profile and "reverse[d] transcriptomic age" in under a week, without the genes. This is the basis of the "longevity pill" talk. | Any animal or human result. These are cells in a dish, measured by transcriptomic clocks. |
| Plesa, Jung … Church, Nature Aging 6, 2057–2073, Oct 2026, 10.1038/s43587-026-01234-8 (added 2026-10-17; abstract read at PubMed 42875585, full text not opened) | human fibroblasts, in vitro → aged mice | Not a Sinclair paper, and not OSK: the abstract states that Yamanaka-factor reprogramming is limited in vivo by "toxicity and efficacy concerns", so a cDNA overexpression screen looked for single factors that shift an aged transcriptome young without loss of cell identity. It found the splicing factor SRSF1. In aged mice, inducible SRSF1 "reduces frailty progression by 44%" and "is associated with a 14% extension of median lifespan" (n = 9–10 per group). The first in vivo lifespan result in this table from a reprogramming-derived screen. | Whether the mice were naturally aged (strain and age at induction not in the abstract ⚠️), any human result, and independent replication. The lifespan effect is reported as an association. Competing-interests statement not read; the last author co-founded Rejuvenate Bio, so check it before citing. |
In one line: OSK works in mouse eyes (peer-reviewed), is reported to work in monkey eyes (conference data only), and is now in a Phase 1 safety trial in human eyes. The pill version exists only in cells in a dish. Every paper above carries a conflict-of-interest statement tying Sinclair to Life Biosciences.
The LEV model: what it is made of
The test. LEV is reached when remaining life expectancy grows by more than one year per calendar year. That is measurable. The US figure at age 65 was 19.7 years in 2024, up 0.2 from 2023 (NCHS Data Brief 548, primary, Jan 2026), and part of that rise is post-COVID recovery. The gauge reads 0.2 against a threshold of 1.0. Every component below is a way of moving that number, and none moves it alone.
| # | component | who | what has to be true | where it stands (2026-09-29) | evidence class |
|---|---|---|---|---|---|
| 1 | Reset: epigenetic reprogramming | Sinclair / Life Bio, Altos, NewLimit, Retro | Partial reprogramming rejuvenates tissue without cancer or loss of cell identity, is repeatable, and can reach the whole body (viral delivery won't; lipid nanoparticles or a small molecule would have to). | Eye: 1 Phase 1 safety trial (ER-100, up to 18 patients, readout May 2027). Interim, sponsor-reported (8 Oct): 3 glaucoma patients at Dose Level 1, no DLT/SAE to Day 56; visual fields improved in 2 of 3; open-label, no control. The next cohort is the registered high-dose glaucoma arm, 6×10¹¹ vg/eye (registry, read 2026-10-17); it is still the Phase 1 safety study, not an efficacy trial. Liver: NewLimit plans a trial in 2027. Whole-body: none. Chemical: cells only. Non-Yamanaka alternative (new 2026-10-17): a single splicing factor, SRSF1, found by a transcriptomic-reprogramming screen, reported to cut frailty progression by 44% and to be "associated with" a 14% median lifespan extension in aged mice, n=9–10 per group (Plesa, Jung … Church, Nature Aging, Oct 2026; abstract only, see The papers). | mouse (peer-reviewed) · primate (conference) · human safety only, in progress |
| 2 | Repair: clearing accumulated damage | de Grey / LEVF, senolytics field | Damage types can be removed faster than they accumulate, and combining interventions adds up. | LEVF's first combination mouse study ended Feb 2025 with a self-described "qualified win": the effects added up, but there was no radical gain in maximum lifespan (self-reported, not peer-reviewed). The next study reports ~2028. | mouse, self-reported |
| 3 | Replace: organs, cells, thymus | Rothblatt / United Therapeutics | Manufactured or gene-edited organs are accepted long-term and made at scale. | Xeno-kidney EXPAND trial: first transplant 2025-11-03; no later one confirmed at the source. Xeno-heart IND: initial cohort up to 2. Manufacturing (new 2026-10-23): a third designated-pathogen-free xenograft facility opened in Houston (release of 2026-10-20), after Christiansburg, Va. (2024) and Stewartville, Minn. (2026-08-12). The release gives no capacity, no transplant count and no BLA date, and says the organs are approved nowhere. Capacity is being built ahead of efficacy data. | first-in-human, single cases |
| 4 | Detect: diagnostics and early detection | Fountain Life, clocks, wearables | Finding disease earlier converts into years, and ageing can be measured in a way regulators accept. | Measurement is sold today. No accepted ageing endpoint, which is why XPRIZE Healthspan scores function (muscle, cognition, immunity) instead of a clock. Bryan Johnson's DunedinPACE figures are self-reported, n=1. | commercial · self-reported |
| 5 | Bridge: lifestyle | everyone; "live long enough" | The bridge buys enough years to reach components 1–3. | The strongest evidence in the model, and bounded. It shifts where you fall inside today's lifespan; it does not move the maximum. | human epidemiology |
| 6 | Accelerant: AI | the Moonshots #293 exhibits; Sinclair's lab ("AI-driven drug design… billions… of molecules", moonshots 251 0:08:00) |
AI shortens discovery and the clinical and regulatory step, which is the slow one. | Discovery is faster (the Insilico molecule reached Phase III, in lung fibrosis). Trials still run on human time: ER-100 needs ~14 months to primary completion. The Amodei and Hassabis quotes are conditional (see ★★ below). | claims · one Phase III (not a lifespan endpoint) |
What the model says. LEV is not one breakthrough. It is 1 × 3 × 4 at population scale, with 5 buying the time and 6 compressing it. Today the only component with human efficacy evidence is 5, and 5 cannot reach escape on its own. The honest place to put LEV on this page is a gauge (0.2 of 1.0) and six dials, not a year.
The predictions, dated, with a read on each
Close = near enough to repeat with a correction. Off = don't repeat. Aspiration: investigate = a forward claim to track, not a fact.
| said | by | date and source | read |
|---|---|---|---|
| 50% chance of LEV by 2036 | de Grey | 2021-03-14, X | Aspiration: investigate. Stated as a probability, which is the honest form. |
| "a greater than 50 percent chance that a 40-year-old living today will never die of old age" | de Grey, as reported | 2026-10-14, New York Times (secondary, search excerpt, not opened ⚠️) | Aspiration: investigate. No year; a probability on a cohort instead. Needs his own words. |
| "fifty-fifty chance of getting there within the next twelve to fifteen years" (comprehensive medical control of ageing); LEV "late 2030s, maybe 2037 to 2040" | de Grey | 2026-11-04, Honest Money LIVE EP 006 (transcript on the episode page, read); 2026-11-07, Kianistan EP 178 (transcript excerpt via search ⚠️) | Aspiration: investigate. Given as a probability again. His own account says his date moved from ~2030 (2004–05) to the late 2030s by 2015 |
| LEV "around 2030" for "the most diligent and informed" | Kurzweil | 2024 book (quoted excerpt ⚠️) | Aspiration: investigate. The condition is part of the claim. |
| LEV "by roughly 2032", starting with the most diligent | Kurzweil | 2025-10-08 MIT lecture, MIT News 2025-10-10 (search extract ⚠️; added 2026-10-29) | Aspiration: investigate. His later date; the condition is kept |
| "by around 2032… people who are diligent with their health… will reach longevity escape velocity"; diligent people "get back as much as four months per year today" | Kurzweil | NextMed Health talk, posted on YouTube 2026-11-05; one listing says it was recorded at NextMed Health 2025 (transcript excerpt via search, video not watched ⚠️; added 2026-11-10) | Aspiration: investigate. The 2032 date is the same as the MIT one, now in his own voice, and the condition is kept. The "four months per year" is his estimate with no source given. The gauge below reads 0.2 years per year for everyone at 65, and his figure is about diligent people only |
| "LEV by the end of 2030" | Peter, attributing it to Kurzweil | Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:13:31 |
Close to Kurzweil, but the condition was dropped |
| "LEV by 2033" | Peter | moonshots 235 onward | Off as a Kurzweil quote (his dates are ~2030 in 2024 and ~2032 in 2025, both conditional). As Peter's own target: Aspiration |
| "one or two more years than 2033" | Rothblatt, accepted by Peter | Moonshots #290 0:22:33 |
Aspiration. The only revision on tape |
| "early 2030s, if not earlier" | Wissner-Gross | moonshots 253 1:17:41 |
Aspiration: investigate |
| "no number" | Sinclair | Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:14:40 |
Close. The defensible position |
| first person to live to 150 already born | Sinclair | same, 0:15:42 |
Aspiration: investigate. Not testable for decades |
| 2026 may be the year age reversal is shown in humans | Sinclair | moonshots 249 0:12:59 |
Aspiration: investigate. The only human study is a safety trial reading out May 2027 |
| ER-100 in humans "January" 2026 | Sinclair | Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:06:05 |
Close. First dosing reported June 2026 |
| "add ten years to healthy human lifespan" | Retro | 2026-05-22, company blog | Aspiration. A healthspan goal, not LEV |
| reverse functional ageing by 10–20 years; prize awarded 2030 | XPRIZE Healthspan | launch 2023-11-29 | Aspiration: investigate. The one prediction with a judged, dated test: watch 2030 |
| "double the human lifespan in the next five to 10 years" | Amodei, as quoted by Peter | Moonshots #293 0:27:26 |
🔴 Off. The conditional was stripped (see below) |
Who is tied to it
This is the short version. The full ledger is in The players, above.
| who | tie |
|---|---|
| Peter Diamandis | adopted "LEV by 2033" as a personal "war cry"; Fountain Life is sold on the bridge-to-LEV frame |
| Ray Kurzweil | the source of the date on this show; also a paid director of Martine Rothblatt's company, disclosed at Moonshots #290 0:11:40 |
| Martine Rothblatt | "my current project with the uh thymus is in fact what I believe I found like the most practical pathway to achieving lev" (0:14:44) — and she sells the therapies |
| Alexander Wissner-Gross | "here comes longevity escape velocity" (moonshots 190 1:31:58) |
The circularity worth holding onto. Kurzweil supplies the date. Kurzweil sits on the board of the company selling the therapy. The therapy's CEO calls the date beyond her risk profile. The host holds the date and owns a stake in the health company that sells the bridge to it. Everyone in the loop is inside the loop. See Moonshots: the disclosures ledger.
The same shape around reprogramming, added 2026-09-29:
- The host is a self-disclosed Life Biosciences investor, and he founded the lab-funding club on air.
- The guest co-founded Life Bio and describes its trial on the show.
- The prize that funds the guest's next human test is run by the host's foundation.
All of it is disclosed somewhere on tape, and none of it in the same breath as the claim.
⚠️ What fails verify-first — do not repeat
From Moonshots #290 (full working in the research archive):
| on tape | reality | verdict |
|---|---|---|
"over uh a 100,000 people on the kidney transplant list" 0:23:16 |
94,015 kidney candidates, OPTN, Dec 2025 (96,366 incl. kidney-pancreas) | overstated — use "about 94,000" |
"another half million people that are not even allowed on the kidney transplant list" 0:23:26 |
the barrier is evaluation attrition, not prohibition — of 720,348 referred patients, 48% never started the evaluation and only 19% completed it (JASN, 2026) | mischaracterised — real problem, wrong mechanism |
heart disease "like a million people a year" 0:25:01 |
~683,000 US deaths, CDC 2024 | ~46% high |
T-cell receptor diversity recognises "more molecules than are estimated to exist in the entire universe" 0:16:49 |
theoretical TCR diversity 10¹⁵–10²⁰; realised repertoire 10⁸–10¹⁰; atoms in the observable universe ~10⁸⁰ | fails by ~60 orders of magnitude |
the thymus "involutes or disappears at age… two" 0:16:18 |
involution begins in the first year and runs ~3%/yr to age 35–45, then ~1%/yr; fat replacement is extensive after ~15. It does not disappear at 2. Peter pushes back on tape (0:16:29) |
do not repeat |
"4 million people that die each year of organ disease" in the OECD 0:43:47 |
no primary source found | unverified |
★ From Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair (the full read, 2026-09-30) — three new failures, and the corpus's cleanest self-contained one
Full working in the research archive §9.
| on tape | reality | verdict |
|---|---|---|
★ Sinclair: extending healthy lifespan by one year is "a value to the US economy of $86 trillion" 0:59:50 — then, unprompted, *"36 or 86? … Wait, we will fact check that."* 1:00:00 |
US$38 trillion. Scott, Ellison & Sinclair, Nature Aging 1, 616–623, 5 Jul 2021, primary: "the total WTP for a 2017 slowdown in aging leading to a 1-year increase in LE is US$37.6 trillion". He is an author | 🔴 Off by ~2.3×. Never repeat 86 |
Peter, 66 min later, reading Gemini aloud: "worth an estimated $38 trillion to the global economy" 2:05:49 |
Number right, scope wrong — the paper is US-only, as Sinclair himself says at 2:04:33 ("It was just US for one year") |
⚠️ Use "US$38 trillion, United States, willingness-to-pay" |
"it was 366 or 7 trillion for 10 years" 1:00:11 |
US$367 trillion, same paper | ✅ correct |
★ Nattokinase: "a study with I think ,086 people… they showed that up to 95% of plaque got removed in one year" 2:07:27, and "at least 6,000 units would be a good start" 2:08:09 |
Frontiers in Cardiovascular Medicine, 2022, n=1,062, retrospective. 66.5–95.4% are "improvement rates" — the share of participants who improved, not the share of plaque removed. Effective arm 10,800 FU/day; 3,600 FU/day reported ineffective; the best RCT (2,000 FU) was null | 🔴 The statistic is inverted and the dose advised is below the study's own null arm. Barred from Gonçalo copy in every form |
"those old mice that they treated lived another 109% longer", attributed to "George Church's lab" 0:47:59 |
Macip et al., Cellular Reprogramming, 2024 — Rejuvenate Bio (Church is a co-founder; not his Harvard lab). 109% is median remaining lifespan in 124-week-old mice: 8.86 → 18.5 weeks, i.e. +9.6 weeks | ⚠️ Literally true, and will be heard as "they lived twice as long." Always say remaining |
Sinclair: "none of our papers have ever been disproved or had to be retracted or changed their conclusions" 1:50:49 |
No retraction found — that word holds. But the flagship Cell 2023 ICE paper carries a published erratum (2024) adding methods detail and prior citations, and drew a formal published critique with a response | Close, one documented exception. ⚠️ An erratum is normal publishing, not misconduct. State it that way or not at all |
🔴 And the hedge-stripping documented below for Moonshots #293 has a 2025 precedent, on this
tape, fifteen months earlier — the same two quotes: Amodei's "doubling of the human lifespan uh
in 10 years time" 0:14:18 and Hassabis's "the end of all disease uh by the end of the decade"
0:14:05, both already stripped of their conditionals here. It is not a one-off. It is a habit
with a history, and the history is on our own disk.
✅ Credit on the same tape. Sinclair explains the willingness-to-pay method correctly
(2:04:43), names his own theory's falsifier specifically and instantly (1:48:11), and reports the
June 2025 Science taurine result — direction and attribution both right — in the month it
published (1:22:08).
From Moonshots #304 (2026-10-21), added 2026-10-23
Full working in the research archive.
| on tape | reality | verdict |
|---|---|---|
Peter: "the GLP-1 drugs are slowing aging by 9%" 1:12:25 |
The 9% is DunedinPACE (pace of ageing on a methylation clock) in a post hoc analysis of a semaglutide-vs-placebo trial: 84 adults with HIV-associated lipohypertrophy, 32 weeks (Nature Communications, 2026, reported June 2026; press coverage, paper not opened ⚠️). The trial was not designed with ageing as an outcome, results vary by clock, and no GLP-1 is approved for ageing. Not new this week. | ⚠️ Scope stripped. Say "one clock, one post hoc analysis, 84 people with an HIV-related condition", or don't say it |
★★ From Moonshots #293 (AMA #2, 2026-09-22) — the four exhibits used to evangelise LEV, and what they actually say
This is the highest-leverage block on this page, because it is not a stray number in a news
segment — it is the set of claims Peter Diamandis says he shows from stages when asked how
to make people believe in longevity escape velocity. The prescription (0:27:01) is good:
"show them evidence after evidence after evidence… show them the data. Not show me the money,
show them the data." The exhibits are the problem. All four checked 2026-09-27.
| exhibit, as said on tape | what the source says | verdict |
|---|---|---|
"the video statements from Dario saying we're going to double the human lifespan in the next five to 10 years" 0:27:26 |
"If you think about what we might expect humans to accomplish in an area like biology in one hundred years, I think a doubling of the human lifespan is not at all crazy. And then if AI is able to accelerate that, we may be able to get that in five to ten years." | 🔴 conditional stripped — never state as a forecast |
"Demis Hassabis talking about curing all disease in the next 10 years" 0:27:36 |
"I think someday we can cure all disease with the help of AI. I think that's within reach within the next decade." | 🔴 four hedges removed |
"Alexander Zhavoronkov from Insilico Medicine, delivering a phase three drug now that is extending life from three to six years from a particular molecule" 0:27:49 |
Phase III is real — rentosertib / ISM001-055, CTR20262475 / NCT07687459, 320 patients, China. But it is an idiopathic pulmonary fibrosis drug and the Phase IIa endpoint was lung function: FVC +98.4 mL at 60 mg QD vs −20.3 mL placebo (Nature Medicine). No lifespan endpoint exists in the programme. | 🔴 the benefit is invented — barred in every form. The true version is stronger: an AI-discovered, AI-designed molecule reached Phase III. |
"David Sinclair… with ER100 in his current human trials" 0:27:40 → "in NAION disease and macular degeneration… he's in phase one trial for safety" 0:57:40 |
Phase 1 correct — Life Biosciences, first patient dosed per a release dated 2026-06-09, NCT07290244, OSK epigenetic reprogramming. Indications: open-angle glaucoma and NAION. | ⚠️ macular degeneration is not an indication. It does trace to Sinclair himself: on moonshots 251 0:21:20 he calls AMD "on the radar… pending results in glaucoma", based on animal data. So it is a future target, not a trial arm |
🔴 And the mechanism given to a caller losing his sight is wrong. At 0:56:20 a caller with
choroideremia (two-thirds of vision lost) asks which path restores sight first. Peter's premise:
"you didn't always have this condition… it is gene expression that occurred later in your
life. And so if you can turn back the gene expression to your earlier state, that should
reverse." Choroideremia is an X-linked monogenic inherited retinal dystrophy (CHM), present
from birth, affecting the RPE and photoreceptors — not age-related epigenetic drift, and not the
cell population ER-100 targets (retinal ganglion cells / optic nerve).
Alexander Wissner-Gross's half is the sound one: Science Corp and Neuralink Blindsight,
fenced as "not medical advice". If this is used on camera, state the mechanism correctly.
★ The pattern, and it is the reason this section exists. "Stack the evidence until the mindset flips" is a volume instruction, and volume is the pressure that rounds hedges off claims. Four exhibits delivered from memory, each a degree stronger than its source, is what stacking looks like when nobody re-reads the primary — and the episode's own cold open then performs the identical compression on the panel's own P(fab) numbers. Source → panelist → clip → repost, one hedge per hop, none of it malicious. The honest version of the prescription: stack the evidence, and cite it — the hedge is the part that makes it defensible and the first thing to fall off. See feedback an input echoed back is not a result and the research archive §8③.
Where it came up
- Moonshots #290 — the whole episode; the date revision at
0:22:33 - moonshots 235 · moonshots 262 · moonshots 201 · moonshots 217 · moonshots 253 — the date
- moonshots 190 · moonshots 264 · moonshots 271 · moonshots 273 — "on the verge of" framings
- ★ Moonshots #293
0:25:33–0:28:46— the evangelism prescription and its four exhibits; a caller doing longevity coaching in the EU asks how do I take people with me, and the answer is "show them the data". Plus0:56:20–0:58:45, the choroideremia exchange. - Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair · moonshots 249 · moonshots 251 — Sinclair as guest: the reset component, from the source
- moonshots 261 — Kurzweil as guest (no LEV year found in the sweep)
- moonshots 279 · Moonshots #294 — de Grey named as the originator, and the origin of the XPRIZE
- Moonshots #288 — the Sinclair return announced, and the Friends of Sinclair Lab disclosure
- Moonshots #301 — the host's Harvard lab visit, "buoyed my belief", no year
- Moonshots #unnumbered
1:04:19,1:10:35–1:11:20,1:12:49,1:19:48— the ER-100 readout relayed on tape (with the "phase three" slip and the "regaining their eyesight" gloss), and three LEV mentions with no year - Moonshots #304
1:09:17,1:12:25–1:12:46— longevity as a federal-debt lever (no year), the GLP-1 "slowing aging by 9%" line, and Wissner-Gross's "spiky LEV" said on tape - Moonshots #305
1:54:37— "when we talk about lev on this podcast this is why we have confidence", on AI-designed proteins and editable biology; no year - Moonshots #308
1:35:00–1:36:56: a listener asks how LEV reaches the poorest; Peter answers with the ER-100 readout, cost figures for AAV gene therapy and SL-100, and XPRIZE Healthspan; no year
⚠️ Unverified
All quotes are from auto-captioned transcripts. Episode numbers are resolved against the live feed
per moonshots_watch.py. The corpus figures (25 episodes, 81 mentions) are from the regex index at
the research archive and count 89 indexed transcripts, not the
full aired history.
Added 2026-09-29, still open:
- Kurzweil's book wording ("around 2030", "the most diligent and informed") is taken from quoted excerpts. It has not been checked against the book.
- The coinage. That de Grey originated the term is the show's attribution (moonshots 279
0:07:58) and the common one. The original paper was not located this pass. - Diamandis's Life Biosciences stake is self-disclosed on tape only. No filing or release was found.
- Sinclair's current Life Bio board seat is not confirmed. "Co-founder" is confirmed (Life Bio release, 2026-06-09).
- The ER-100 first-dosing day. The release is dated 2026-06-09 and does not give the day.
- Primate "95%" and the XPRIZE chemical-cocktail human trial: no peer-reviewed paper and no registry entry found.
- Hevolution's dollar contribution to XPRIZE Healthspan is not verified at the source.
"40 million" and Chip Wilson's "36 million" are Peter's figures (Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair
0:31:02). - About 6,000 US NAION cases a year is a secondary estimate (AAO EyeNet). The 2.3–10.2 per 100,000 base rate is from population studies in the 1990s.
- Not ingested: Sinclair's 2022 and 2023 appearances (EP #18, AMA, EP #60). ✅ Resolved 2026-09-30: the 2h23 of the 2025 episode is now read end to end, so "Sinclair never gives a LEV year" is bounded to the four appearances ingested, not three.
- Unverified in the 2025 episode, still open: the XPRIZE sponsor splits ($157M raised / Chip
Wilson $36M / Hevolution $40M) are Peter's figures and are not confirmed at the source; the
"sister's menopause age correlates with your lifespan" claim (
1:42:53); and the Swedish pension-indexation claim (1:59:23). - Which researcher appeared with Sinclair (Yamanaka's factors, or Keio's Hayano and Tsubota as co-authors) is open.
Added 2026-10-17:
- ✅ Resolved: the 2026-10-11 note that "the Dose Level 2 vector dose was not confirmed." The registry has carried a high-dose glaucoma arm at 6×10¹¹ vg/eye and a NAION cohort (3, expandable to 6) since the record was posted; Dose Level 2 is that arm, not a new cohort.
- The SRSF1 paper (Nature Aging, Oct 2026): abstract only; mouse strain, age at induction and the competing-interests statement are not read.
- "Spiky LEV" (Wissner-Gross, X, 2026-10-13) and the NYT line on de Grey (2026-10-14) are from search excerpts; neither source was opened directly.
- De Grey's 2026-10-16 podcast interview is not read; no claim has been taken from it.
- Altos Labs lists a CMO appointment (Joan Mannick) with no date on its site; whether it falls in the window is unknown.
Added 2026-10-23:
- The semaglutide 9% paper (Nature Communications, 2026) is known from press coverage and the EP304 anatomy; the paper itself was not opened on this page.
- Retro's RTR242 Phase 1 was reported (secondary, a newsletter, not Retro) to have expanded from 76 to 108 healthy volunteers in August 2026. Retro's own blog shows one undated post; not confirmed at the source.
- Altos funding "approaching $6 billion" (secondary, attributed to the WSJ) is unconfirmed; the page keeps the primary $3 billion.
Added 2026-10-29:
- Kurzweil's "roughly 2032" is MIT News's report of his 8 Oct 2025 lecture, read through a search extract; the page and the lecture video were not opened directly.
- The coinage, a lead: a documentary of 24 Oct names de Grey's 2004 PLoS Biology essay "Escape velocity: why the prospect of extreme human life extension matters now" as the origin (secondary). A PubMed title search under his name returned 0; not confirmed at the journal.
- The speaker at Moonshots #305
1:54:37is inferred from the hand-off (Peter: "Alex, your take" at1:53:00); auto-captions carry no labels.
Added 2026-11-10:
- ✅ Resolved: de Grey's "12–15 years" is no longer a paraphrase. His own words are on the 4 Nov Honest Money transcript (read on the page). The page's transcript stops about two-thirds of the way through, so the rest of the interview was not read.
- De Grey's 7 Nov interviews (Futureproof Report; Kianistan EP 178) and Kurzweil's NextMed talk (posted 5 Nov) are known from transcript excerpts found by search. None of the videos were watched. Whether the NextMed talk was recorded in 2025 depends on one listing's description.
- On Moonshots #308: the "half a million to two million dollars" AAV cost and the SL-100 "200 dollars per month" are the host's figures and have no primary source. They are also open on David A. Sinclair. His "slowing down aging… for 20 years" is a loose description of XPRIZE Healthspan, which aims to restore function by at least 10 years, with 20 as the stretch target. The captions are machine-translated ⚠️.
- This week's PubMed hits were sorted using PubMed's publication-type and subject filters. The individual records were not opened, because the record pages showed a cookie wall and the metadata call was not permitted.
How this page stays current
One pull a week (the vault-weekly engine, Mondays). Each step names the source and what to diff:
- Moonshots. Read the research archive and any new episode directory
(the moonshots lane ingests; this page does not download). Grep new transcripts for
escape velocity|LEV|Sinclair|de Grey|Kurzweil|Yamanaka|reprogramming|Healthspan.- Diff: add a row to The date, across the corpus for every new dated LEV claim, with speaker and timestamp.
- Sinclair's return episode (announced on Moonshots #288): when it airs, it gets a row in David Sinclair on Moonshots and a full read.
- Trials. Re-open NCT07290244 (ER-100) and
search ClinicalTrials.gov for
partial reprogramming,OSK,NewLimit,Retro Biosciences,RTR242,Altos.- Diff: status, enrolment, primary-completion date, and any posted results. Move the component 1 row when anything changes.
- Companies. Check the news pages of Life Biosciences, NewLimit (blog), Retro (blog) and Altos
Labs, the United Therapeutics investor-relations releases (EXPAND, UHeart), and LEV Foundation
updates.
- Diff: new rounds, first-in-human dates, published results.
- Prize. Check XPRIZE Healthspan news.
- Diff: milestone dates, finalist changes, rule or age-band changes.
- Open calls go to
submissions/pipeline.json(theopportunities:terms on this page feed the site's Open calls box).
- Journals. Run a PubMed query for the last 7 days:
(partial reprogramming OR epigenetic reprogramming OR OSK) AND (aging OR ageing), plusSinclair DA[au]. Check Nature Aging, Cell, Nature, Aging Cell and Aging (Albany). Screen bioRxiv/medRxiv under "cell biology / geriatric medicine".- Diff: any in vivo result in a normally ageing animal, any human result, any retraction or erratum on a paper in The papers table.
- Forecasts. Check the X posts of @aubreydegrey and @RayKurzweil, plus Kurzweil interviews.
- Diff: any new LEV year or probability goes in the predictions table with its date and its condition.
- The gauge. Once a year, when the NCHS Mortality in the United States brief is published (January), update the life-expectancy-at-65 change. That is the one number LEV is actually measured by.
- Close the page. Write a one-line This week entry below, and bump
updated:and the Updated line. Anything not re-read at the source stays marked ⚠️. No medical advice, no personal colour, capture not rulings.
This week (2026-09-29): baseline edition. Players, the six Sinclair appearances, the papers, and the model added.
2026-09-30: the 2025-06-25 Sinclair episode read end to end (was swept). Three new verify-first failures added, including the corpus's cleanest self-contained one ($86T → $38T, fact-checked by an LLM on its own tape and never reconciled). Sinclair split out to his own page, David A. Sinclair. The Amodei/Hassabis hedge-stripping is now dated to 2025, not 2026.
2026-10-01: moonshots 261 (the Kurzweil guest episode) read end to end — the oldest undecomposed episode on disk. Kurzweil split out to his own page, Ray Kurzweil (promoted: cited in ≥2 episodes, no page before this run). No new LEV date — he restates AGI 2029/singularity 2045, not an LEV year — but the page now links through to his model, his ties and the caption-mangle note that explains why he was invisible to the regex index.
2026-10-05: no new LEV date or probability found. What moved, all checked at source:
- Component 1 (reset), upcoming: Life Biosciences announced (release of 2026-10-01) that interim first-in-human ER-100 data from the Phase 1 glaucoma cohort will be presented on 2026-10-08, 2:10 pm CT, Eyecelerator @ AAO, New Orleans (presenter Sharon Rosenzweig-Lipson). No results are public yet; re-read after the 8th. NCT07290244 is unchanged: Recruiting, up to 18 (estimated), primary completion May 2027, last update 2026-05-19.
- Prize: XPRIZE Healthspan page unchanged (20 finalists, 10 awarded $1M each on 2026-08-11). The discretionary late-registration window (Aug 2026–Jul 2027, $100,000 fee) states there are no open spots.
- Journals: PubMed, 2026-09-28 to 2026-10-05, reprogramming/OSK + ageing: 10 hits, all review papers or cell-culture work (e.g. Aging Cell, human blood to neural stem cells; Basic Res Cardiol, endothelial cells). No in vivo result in normally ageing animals, no human result, no erratum or retraction on a paper in The papers table.
- Moonshots: EP297 and EP298 are on disk and undecomposed; the regex sweep found no LEV, Sinclair, de Grey or Yamanaka mention (one unrelated "cell reprogramming" joke in EP297). EP299 (aired this week) is not on disk. Sinclair's return episode has not aired.
- Not changed: LEV Foundation's site shows no post since 2026-03-25; United Therapeutics' releases list shows nothing on EXPAND/UHeart in the window (latest 2026-09-30, patent litigation). Altos, NewLimit and Retro: a search surfaced no new news in the window; their own pages were not re-opened this pass, so those rows stay as of 2026-09-29. Kurzweil and de Grey X feeds were not re-read. ⚠️
2026-10-11: one new LEV statement on tape, no year in it; one primary-source readout. All checked at source.
- Moonshots: the 7 Oct episode (Moonshots #301, decomposed 8 Oct, Whisper captions, no speaker
labels, speaker inferred as Peter) has the host saying he visited Sinclair's lab at Harvard Medical School
the day before, for its 25th anniversary: "It just buoyed my belief in reaching longevity escape
velocity" (
0:15:06). No year, no probability: nothing goes in the date table. He also said the lab is "going to be unblinding the data from the phase one trial" (0:14:19). The trial is open-label, so "unblinding" is loose wording; the data came out the next day (below). He repeats the Friends of Sinclair Lab raise ("$6 million",0:15:27, his figure, unaudited). Sinclair's return episode has not aired. - Component 1 (reset), the readout: Life Biosciences' release of 2026-10-08 (company release, read at lifebiosciences.com; trade coverage agrees) reports first-in-human interim ER-100 data presented at Eyecelerator @ AAO: 3 open-angle glaucoma participants, Dose Level 1 (2×10¹¹ vg, single intravitreal injection plus daily oral doxycycline), well tolerated to Day 56, no DLT, SAE or AESI; ≥4 dB improvement at ≥28% of visual-field locations in 2 of 3; the DSMB recommended escalation to Dose Level 2. Read it as a sponsor-reported, open-label n=3 safety readout, not efficacy; the company frames the study that way. The earlier "re-check in 2027" for Sinclair's 2026 age-reversal line stands. Registry NCT07290244 not yet updated: Recruiting, up to 18 (estimated), primary completion May 2027, last update 2026-05-19. The Dose Level 2 vector dose was not confirmed. ⚠️
- Prize: XPRIZE Healthspan main track unchanged (20 finalists, 10 awarded $1M on 2026-08-11; late registration: no open spots; page age band now reads 50–80; Finalist FAQ Issue 4 dated October 2026). The page also lists a $10M FSHD Bonus Prize track ($1,000 registration for commercial teams, no stated deadline); added to the pipeline as a watch row.
- Journals: PubMed, 2026-10-04 to 2026-10-11, reprogramming/OSK + ageing: 4 hits (three reviews, one
bioRxiv preprint on epigenetic age in iPSC-derived tissues). No in vivo result in normally ageing
animals, no human result, no erratum or retraction on a paper in The papers table.
Sinclair DA[au]was not re-run on this page this pass (the David A. Sinclair page's own run found 0). - Not changed / not re-read: United Therapeutics, NewLimit, Retro, Altos, LEV Foundation: a search surfaced no new items in the window; their own pages were not re-opened, so those rows stay as of 2026-09-29. Kurzweil and de Grey X feeds were not re-read. ⚠️
2026-10-17 (window 11–17 Oct): no new LEV year or probability on tape; one new framing, one in vivo paper, one open item resolved. All checked at source unless marked.
- Moonshots: the 15 Oct episode (Moonshots #unnumbered, unnumbered, Whisper captions, speakers
inferred) carries LEV four times, no year. Peter
1:04:19: "I could not be more excited about this area, pushing us towards longevity escape velocity", opening his Abundance longevity trip (40 scientists, San Francisco; Sinclair "was there talking about his epigenetic reprogramming"). Peter1:10:35–1:11:20relays the ER-100 readout: "phase three is a safety trial" (a slip for phase one; the next line is "It came back safe"), "two out of the three patients started regaining their eyesight" (the company's wording is visual-field improvement at ≥28% of locations, open-label, n=3, efficacy not established), and "They're gonna go now to a efficacy trial" (🔴 off: the DSMB cleared the next dose level of the same Phase 1 safety study). Peter1:12:49: "I'm the oldest of the four of us, so I'm… so pumped about longevity escape velocity, I can't stand it." Wissner-Gross1:19:48: LEV, nanotech and superintelligence land "at approximately the same time", no date. Nothing goes in the date table. The watch file (checked 17 Oct 11:00 UTC) shows 104 on disk, nothing missing: Sinclair's return episode has not aired. - Forecasts: Wissner-Gross put "Spiky LEV" in writing on X, 13 Oct (added to The players; search excerpt, not opened). De Grey: a new podcast interview posted 16 Oct (not read) and a NYT line of 14 Oct (added to the predictions table as secondary). Kurzweil: no new statement found; a 12 Oct Malaysian column repeats "by about 2029" from his 2024 material (secondary, not his words this week). Also in the window, as dissent off the tape: Seamus O'Mahony's book The Longevity Delusion (Telegraph, 15 Oct): "No intervention whatsoever has ever been shown to delay the ageing process in humans" (secondary).
- Trials: NCT07290244 read via the registry API: unchanged. Recruiting, 18 estimated, primary completion 2027-05, completion 2032-03, last update posted 2026-05-19, no results section. The registered arms resolve last week's open item (see Unverified, 2026-10-17).
- Companies: Life Biosciences news page: nothing after 8 Oct (its X of 13 Oct, per the David A. Sinclair refresh, says the CSO's Eyecelerator talk won a People's Choice award; no new numbers). NewLimit blog: newest post 10 Jul 2026. Retro blog: only the fundraise post, no RTR242 result. Altos: no dated news, no human trial. LEV Foundation: newest item 25 Mar 2026 (an HLI collaboration), no post since. United Therapeutics releases: 13 Oct (CHEST data) and 14 Oct (Liquidia settlement), nothing on EXPAND or UHeart. Rows 2 and 3 of the model stand.
- Prize: XPRIZE Healthspan page unchanged from 11 Oct (20 finalists; late registration: no open spots; age band 50–80; Finalist FAQ Issue 4, October 2026; FSHD bonus track still without a stated deadline). No new open call found; the two existing pipeline rows were re-swept.
- Journals: PubMed, 2026-10-10 to 2026-10-17, reprogramming/OSK + ageing: 12 hits; 9 reviews, 2 bioRxiv
preprints (iPSC epigenetic age; a neuronal spheroid platform), and one in vivo result in aged animals:
Plesa, Jung … Church, Nature Aging, SRSF1 (added to The papers and to component 1). It is not OSK and not
Sinclair; it is the first paper on this page to move mouse lifespan from a reprogramming screen, and it is
small (n=9–10).
Sinclair DA[au]: 0. No erratum or retraction on a paper in The papers table was found for Sinclair's papers (the David A. Sinclair run of 17 Oct); the Yamanaka 2006 and Ocampo 2016 records were not re-checked this pass. ⚠️ - The gauge: annual, next in January 2027. Still 0.2 of 1.0.
2026-10-23 (window 17–23 Oct): no new LEV year or probability anywhere. One mention on tape, one manufacturing step on component 3, nothing else moved. All checked at source unless marked.
- Moonshots: watch file (checked 23 Oct 11:00 UTC) shows 106 on disk, nothing missing. EP303 (17 Oct):
zero hits for LEV, Sinclair, de Grey, Kurzweil, Yamanaka, reprogramming, Healthspan or longevity. EP304
(Moonshots #304, 21 Oct, auto-captions, speakers inferred): longevity named as a debt-cutting lever
(
1:09:17, no year), Peter's "GLP-1 drugs are slowing aging by 9%" (1:12:25, scope stripped, see What fails verify-first), and Wissner-Gross: "we may already be in spiky LEV" (1:12:35), the 13 Oct X framing now said on tape. No year: nothing goes in the date table. Sinclair's return episode has not aired. - Trials: NCT07290244 via the registry API: unchanged. Recruiting, 18 estimated, primary completion 2027-05, completion 2032-03, last update posted 2026-05-19, status verified 2026-03, no results.
- Companies: Life Biosciences news page: newest item still 8 Oct. United Therapeutics, 20 Oct: third designated-pathogen-free xenograft facility opened in Houston (release read at ir.unither.com; no capacity, transplant count or BLA date given); added to component 3. UTHR's other releases in the window (19 Oct SUMMIT/PH-COPD, 21 Oct Q3 date, 22 Oct buyback) are not LEV. LEV Foundation: newest item still 25 Mar 2026. Retro blog: one undated post (the fundraise). NewLimit blog: post list not readable this pass ⚠️; a search surfaced nothing dated in the window. Altos: nothing dated in the window found.
- Prize: XPRIZE Healthspan page unchanged (20 finalists, 10 Milestone 2 awardees at $1M; late registration
Aug 2026–Jul 2027, no open spots, $100,000; age band 50–80; FSHD bonus $10M, $1,000 commercial registration,
still no stated deadline; newest dated news 11 Aug). No new open call, so no new
pipeline.jsonoroperator_guide.jsonrow; the existing Healthspan/FSHD rows stand. - Journals: PubMed, entry date 2026-10-16 to 2026-10-23, reprogramming/OSK + ageing: 7 hits, all reviews,
perspectives or cell work (incl. a circRNA partial-reprogramming platform in mesenchymal stem cells). No in
vivo result in normally ageing animals, no human result.
Sinclair DA[au]: 0. No erratum or retraction on a paper in The papers table surfaced; those records were not individually re-opened. ⚠️ - Forecasts: no new statement from de Grey or Kurzweil found by search; their X feeds were not read directly. ⚠️ De Grey's 16 Oct podcast interview is still unread.
- The gauge: still 0.2 of 1.0; next NCHS brief January 2027.
2026-10-29 (window 23–29 Oct): no new LEV year or probability from anyone on the page. One passing mention on tape, one older Kurzweil date added, two in vivo mouse papers; trials, companies and the prize did not move. All checked at source unless marked.
- Moonshots: watch file (checked 29 Oct 11:01 UTC) shows 108 on disk, nothing missing. EP305
(Moonshots #305, 23 Oct, auto-captions, speaker inferred as Wissner-Gross): "when we talk about lev on this
podcast this is why we have confidence that we're in the middle of this you know healthspan revolution"
(
1:54:37), on AI-designed proteins; no year, so nothing goes in the date table. EP306 (28 Oct, undecomposed): zero hits for LEV, Sinclair, de Grey, Kurzweil, Yamanaka, reprogramming, Healthspan or longevity. Sinclair's return episode has not aired. - Forecasts: Kurzweil's "by roughly 2032" (MIT, 8 Oct 2025) resurfaced in coverage on 29 Oct and was not on this page; it is added to The date and to the predictions table. It is a year old, not new. De Grey: no new statement found; the coverage this week repeats older lines (the NYT line of 14 Oct, the "1,000 years" claim). His 16 Oct interview is still unread. ⚠️ Off the tape, the founder of a commercial longevity clinic said on a podcast that the clinic's clients have "already reached longevity escape velocity", measured by a proprietary biomarker model of predicted life expectancy (transcript excerpt, upload date not confirmed ⚠️). That is a model forecast for self-selected clients, not remaining life observed, so it does not meet this page's definition and is not placed in the table.
- Trials: NCT07290244 via the registry API: unchanged. Recruiting, 18 estimated, primary completion 2027-05, completion 2032-03, last update posted 2026-05-19, status verified 2026-03, no results. One newsletter (29 Oct) says Dose Level 2 is "completing"; the registry and the company say nothing of it, so it is not taken. ⚠️
- Companies: Life Biosciences news page: newest item still 8 Oct. United Therapeutics: one release in the window (28 Oct, an inhaled treprostinil-iloprost trial in PAH), not LEV; the 20 Oct xenograft facility stands as the newest organ item. LEV Foundation: newest item still 25 Mar 2026. Retro blog: the one undated fundraise post. NewLimit blog: the post list still does not load ⚠️. Altos: nothing dated found.
- Prize: XPRIZE Healthspan page unchanged (20 finalists; late registration Aug 2026–Jul 2027, no open spots,
$100,000; age band 50–80; FSHD bonus $10M, $1,000 commercial registration, no stated deadline; newest dated
news 11 Aug). No new open call, so no new
pipeline.jsonoroperator_guide.jsonrow. - Journals: PubMed, entry date 23–29 Oct, reprogramming/OSK + ageing: 11 hits, 6 reviews. Of the rest, two bear
on component 1, both in aged mice and neither on lifespan: cyclic OSKM before an induced stroke gave smaller
lesions and better neurological scores (Aging Cell, Nov 2026, small groups, n=5–8, abstract only); and a
re-analysis of existing RNA-seq from aged mice after seven months of cyclic Yamanaka-factor expression found
less inflammation in liver and kidney and "a potential risk of sustained genomic and proliferative stress" in
the spleen (Aging (Albany), 27 Oct, abstract only). The other two use "reprogramming" in an unrelated sense.
Sinclair DA[au]: 0. No erratum or retraction surfaced on a paper in The papers table; those records were not re-opened. ⚠️ Also surfaced in coverage, not new and not reprogramming: SRN-901 (Weiss … , Drug Des Devel Ther, dated 15 Apr 2026), a five-ingredient oral combination given to 18-month-old C57BL/6J mice on a Western diet: median remaining lifespan 263.5 → 350.5 days (+33%, HR 0.54). All authors but two are employees or shareholders of the company that developed it (the other two list its China joint venture, per a secondary thread), and the company sells a related supplement. One lab, one strain, no human data. Captured here as a mouse result, not placed in the model. - The gauge: still 0.2 of 1.0; next NCHS brief January 2027.
2026-11-04 (window 29 Oct–4 Nov): nothing changed — no new LEV year or probability from anyone on the page, no trial change, no company result, no new open call. Dated, checked at source unless marked.
- Moonshots: watch file (checked 4 Nov 12:00 UTC) shows 109 on disk, nothing missing. The one new episode,
EP307 (Moonshots #307, decomposed 2 Nov, auto-captions, speakers inferred): zero hits for LEV, escape
velocity, Sinclair, de Grey, Kurzweil, Yamanaka, reprogramming or Healthspan. One passing longevity exchange
(
0:07:38): Musk's one-line X reply "Longevity is coming" (30 Oct, verified primary in the episode anatomy), met with a joke about Tesla pivoting to GLP-1s. No year, no LEV: nothing goes in the date table. Sinclair's return episode has not aired. - Forecasts: no new statement from de Grey or Kurzweil found by search; their X feeds were not read directly. ⚠️ De Grey's 16 Oct podcast interview is still unread.
- Trials: NCT07290244 via the registry API: unchanged. Recruiting, 18 estimated (12 OAG + 6 NAION), primary completion 2027-05, completion 2032-03, last update posted 2026-05-19; the results-section field was not re-verified this pass (truncated response) ⚠️. A registry search for partial reprogramming / NewLimit / Retro / RTR242 / Altos returned no study updated in the window (the query matched no studies at all, so a weak negative ⚠️).
- Companies: Life Biosciences news page: newest item still 8 Oct. United Therapeutics: three releases in the window (28 Oct treprostinil-iloprost IND in PAH; 4 Nov Q3 results and a ralinepag royalty buydown), none organ or xeno; the 20 Oct Houston xenograft facility stands as the newest organ item. Retro blog: the fundraise post, now carrying a date, 22 May 2026 (resolves the 10-23 "undated" note); no RTR242 result. NewLimit blog: the post list still does not load ⚠️. LEV Foundation and Altos Labs news pages both returned 404 this pass, so neither was read ⚠️ — the one dated Altos item this week arrived via PubMed instead (below).
- Prize: XPRIZE Healthspan page unchanged (20 finalists, 10 Milestone 2 awardees at $1M; late registration
Aug 2026–Jul 2027, no open spots, $100,000; age band 50–80; FSHD bonus $10M, $1,000 commercial registration,
no stated deadline). One correction: the newest dated news item is the 15 Oct Impact Report 2026, not
11 Aug — before this window, so nothing new. No new open call, so no new
pipeline.jsonoroperator_guide.jsonrow. - Journals: PubMed, entry date 28 Oct–4 Nov, reprogramming/OSK + ageing: 9 hits — 6 reviews, 2 cell works,
and one in vivo item that is the same Aging (Albany) 27 Oct re-analysis already captured in the
10-29 entry (PubMed entry lag, not a new result). Of the cell works, one is Altos Labs' first dated output
on this page since launch coverage: an optimized ATAC-see imaging method for the chromatin landscape of
ageing and reprogramming in cells and fixed tissue sections (J Cell Sci, Epub 30 Oct; Izpisua Belmonte an
author; "All authors are current employees of Altos Labs and hold equity"). A method paper, not a trial —
component 1 does not move. No in vivo result in normally ageing animals beyond the already-captured one, no
human result.
Sinclair DA[au]: 0. No erratum or retraction surfaced on a paper in The papers table; those records were not individually re-opened. ⚠️ - The gauge: still 0.2 of 1.0; next NCHS brief January 2027.
2026-11-10 (window 4–10 Nov): no new year from anyone on the tape. Off the tape, both forecasters gave their dates again in their own voices. De Grey's "12–15 years" is now a quote, not a paraphrase. Trials, companies and the prize did not move, and there is no new open call. Checked at source unless marked.
- Moonshots: the watch file (checked 10 Nov 12:00 UTC) shows 111 on disk and nothing missing. EP308
(Moonshots #308, 4 Nov, machine-translated captions, speakers inferred) has one LEV exchange in the AMA
(
1:35:00). A listener asks how LEV reaches the poorest. Peter names sleep, diet and exercise first, then the ER-100 Phase 1 data, "half a million to two million dollars" per AAV treatment, SL-100 at an estimated "$200 per month", and the $101M XPRIZE Healthspan. No year, so nothing goes in the date table. The cost figures have no primary source (see Unverified). EP309 (7 Nov, Whisper captions) has one "escape velocity", and it is "super intelligence escape velocity", not LEV, so there is no hit. Sinclair's return episode has not aired. - Forecasts: de Grey, Honest Money LIVE EP 006 (4 Nov, transcript read on the page): "fifty-fifty chance of getting there within the next twelve to fifteen years", where "there" means comprehensive medical control of ageing. On 7 Nov (Futureproof Report; Kianistan EP 178, transcript excerpts ⚠️) he gave LEV as 50/50 within 12–15 years, and also as "late 2030s, maybe 2037 to 2040", saying his date slipped from ~2030 to the late 2030s by 2015. Both are added to The players and the predictions table. Kurzweil: a NextMed Health talk posted 5 Nov (possibly recorded in 2025 ⚠️) repeats "by around 2032" for "people who are diligent with their health" and adds that the diligent "get back as much as four months per year today". That is his estimate, with no source, and it is not comparable to the population gauge. It is added to the predictions table. The X feeds were not read directly ⚠️. Also in the window, off the page's cast: OpenAI's Greg Brockman said at WSJ Tech that death could become "a choice", with no therapy, method or date (secondary, 5–8 Nov coverage). That is not an LEV claim, so it is not placed.
- Trials: NCT07290244 via the registry API: unchanged. Recruiting, 18 estimated, primary completion 2027-05, completion 2032-03, last update posted 2026-05-19, status verified 2026-03, no results. The same three arms (OAG 2×10¹¹, OAG 6×10¹¹, NAION selected dose). Coverage this week calls Dose Level 2 "now enrolling". The registry does not say so and the company has said nothing since 8 Oct, so that is not taken ⚠️.
- Companies: United Therapeutics' Q3 results (4 Nov, Exhibit 99.1 read at EDGAR) contain no xenotransplant milestone. They do not mention EXPAND, EXTEND, UKidney or UHeart, only higher spending on "manufactured organ" projects and the Thymmune acquisition. A secondary write-up says the Phase 1 EXTEND study of UThymoKidney "has been completed". It is not in the release (it may be in the 10-Q, which was not read ⚠️), so component 3 does not move. A 9 Nov release covers investor conferences only. Life Biosciences: search surfaced nothing after 8 Oct, and the news page was not re-opened ⚠️. NewLimit, Retro, Altos, LEV Foundation: search surfaced only re-reports of old rounds (NewLimit $435M in June; Retro $1.8B pre-money in May), nothing dated in the window. Their own pages were not re-opened ⚠️.
- Prize: the XPRIZE Healthspan page (read 10 Nov) is unchanged: 20 finalists; late registration Aug 2026–Jul
2027 with no open spots, $100,000; age band 50–80; FSHD bonus $10M, $1,000 commercial registration, no stated
deadline, "interested teams may still join". The newest dated item is still the 15 Oct Impact Report 2026.
The 2026 Innovation Landscape Report was shared on social media on 6 Nov, but it is dated 7 Aug. No new open call, so there is no
new
pipeline.jsonoroperator_guide.jsonrow. The existing Healthspan/FSHD rows stand. - Journals: PubMed, entry date 4–10 Nov, reprogramming/OSK + ageing: 5 hits. Four are reviews. The fifth
matches none of the animal, human, lifespan or in-vivo filters. No in vivo result in normally ageing
animals, and no human result.
Sinclair DA[au](3–10 Nov): 0. No erratum or retraction on a paper in The papers table surfaced; those records were not opened ⚠️. - The gauge: still 0.2 of 1.0; the next NCHS brief is due January 2027.
2026-11-16 (window 10–16 Nov): nothing changed. Nobody on the page gave a new LEV year or probability. The trial, the companies and the prize did not move, and there is no new open call. Checked at source unless marked.
- Moonshots: the watch file (checked 16 Nov 14:43 UTC) shows 113 on disk and nothing missing. EP310 (11 Nov,
auto-captions) has one passing "longevity" (
2:00:36): the host mentions a podcast he did on longevity. It has no LEV, no year and no therapy. EP311 (13 Nov) has no hits for LEV, escape velocity, Sinclair, de Grey, Kurzweil, Yamanaka, reprogramming, Healthspan or longevity in its transcript. One chapter is titled "Can AI Cure Chronic Disease Within a Decade?", but nothing in that chapter matches those terms. Nothing goes in the date table. Sinclair's return episode has not aired. - Forecasts: de Grey was on two new shows: BBC Radical with Gabriel Gatehouse (published 12 Nov, 50 min) and The 200 Year Life Project (posted 12 Nov). Neither was listened to. Their descriptions repeat the "first person to reach 1,000 may already have been born" line and say people around 60 are likely to get the first rejuvenation treatments. Neither description gives a year. A four-way panel on The Beyond Tomorrow Podcast has a description that gives de Grey "50/50 chance within 12 to 15 years". That matches the 4 Nov quote above, so it adds nothing new. The same description gives Alex Zhavoronkov (Insilico) as "20 to 50 years". That is new to this page, but it comes from the episode description only, and the episode's date and his exact words are not confirmed ⚠️, so it is not added to the predictions table. Kurzweil: one repost (3 Quarks Daily, 13 Nov) of a talk on AI and lifespan. The talk was not watched and no new year was found ⚠️. The X feeds were not read directly ⚠️. A 12 Nov essay repeats de Grey's "50-50 by 2035" from older material, which is secondary and not new.
- Trials: NCT07290244 via the registry API is unchanged. Recruiting, 18 estimated, primary completion 2027-05, completion 2032-03, last update posted 2026-05-19, status verified 2026-03, hasResults false. It has the same three arms (OAG 2×10¹¹ vg/eye, OAG 6×10¹¹ vg/eye, NAION selected dose). A registry search for partial reprogramming / OSK / NewLimit / RTR242 / Altos / Retro returned 47 studies. The only one updated since 9 Nov is an unrelated metformin lung-cancer trial.
- Companies: the Life Biosciences news page's newest item is still 8 Oct. Coverage this week (Healio, 13 Nov; Boston Globe opinion, 12 Nov) re-reports the 8 Oct readout and adds no new numbers. United Therapeutics had one release in the window, 9 Nov (investor conferences). Its title and summary do not mention xeno; the full text was not read. LEV Foundation's newest item is still 25 Mar 2026. Retro's blog still has only the fundraise post. NewLimit's blog returned 404 ⚠️. For Altos and NewLimit, a search surfaced only re-reports of old rounds.
- Prize: the XPRIZE Healthspan page (read 16 Nov) is unchanged: 20 finalists; late registration Aug 2026–Jul
2027 with no open spots and a $100,000 fee; age band 50–80; FSHD bonus $10M, $1,000 commercial registration,
no stated deadline, "interested teams may still join". The newest dated item is still the 15 Oct Impact
Report 2026. No new open call, so there is no new
pipeline.jsonoroperator_guide.jsonrow. The existing Healthspan/FSHD rows stand. - Journals: PubMed, entry date 9–16 Nov, reprogramming/OSK + ageing: 10 hits (PMIDs 43011204–43034819). The
records were not opened this pass, because the metadata call was not permitted ⚠️. So it is not
established whether any is an in vivo result in normally ageing animals or a human result. Re-screen next
week.
Sinclair DA[au](9–16 Nov): 0. No erratum or retraction on a paper in The papers table surfaced; those records were not opened ⚠️. - The gauge: still 0.2 of 1.0; the next NCHS brief is due January 2027.